Singapore: Australia based biotech company, Proteomics International Laboratories, has produced and validated a predictive test called PromarkerDfor the diagnosis of diabetic kidney disease (DKD).

PromarkerD is a proteomics-derived predictive (prognostic) test for the diagnosis of DKD, and represents a global breakthrough in the diagnosis and treatment of the disease.

The ability to accurately predict the onset of DKD via a simple blood test and then provide appropriate clinical treatment to prevent the onset of the disease has the potential to save health care systems globally billions of dollars. In Australia, the total cost to the health system and in productivity loss attributed to diabetes is estimated at be about $10.3 billion annually.